Skip to main content
Retour
Watch Compare

Curanex Pharmaceuticals Inc

Qualité des données : 83%
CURX
Nasdaq Manufacturing Chemicals
0,46 €
▼ 0,01 € (-2,62%)
Cap. Boursière: 13,28 M
Prix
0,47 €
Cap. Boursière
13,28 M
Fourchette du Jour
—
Fourchette 52 Semaines
—
Volume
—
Ouverture —
Moyenne 50J / 200J
—
Moyenne 50J / 200J
—

Quick Summary

Points Clés

Negative free cash flow of -10,48 M

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-57,89%
En dessous de la moyenne du secteur (-53,41%)
ROIC-44,64%
Net MarginN/A
Op. MarginN/A

Sécurité

Debt / Equity
N/A
Current Ratio77,53
Interest Coverage-496,55

Valorisation

PE (TTM)
-3,14
En dessous de la moyenne du secteur (-1,48)
P/B Ratio0,93
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -3,1 -1,5
P/B 0,9 1,6
ROE % -57,9 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -4,23 M
ROE -57,89% ROA -55,36%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -10,48 M
ROIC -44,64% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 77,53
Interest Coverage -496,55 Asset Turnover N/A
Working Capital 14,23 M Tangible Book Value 14,29 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -3,14 Forward P/E N/A
P/B Ratio 0,93 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -78,93%
Market Cap 13,28 M Enterprise Value 7,48 M
Per Share
EPS (Diluted TTM) -0,17 Revenue / Share N/A
FCF / Share -0,37 OCF / Share -0,37
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 248,15%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025
Revenue —
Net Income -4,23 M
EPS (Diluted) -0,17
Gross Profit —
Operating Income -4,24 M
EBITDA —
R&D Expenses 2,99 M
SG&A Expenses —
D&A —
Interest Expense 8 537,0
Income Tax —

Balance Sheet

Annual, most recent first
Metric FY2025
Total Assets 11,58 M
Total Liabilities 361 040,0
Shareholders' Equity 11,22 M
Total Debt —
Cash & Equivalents 5,00 M
Current Assets 11,23 M
Current Liabilities 137 030,0